It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tissue repair and healing remain among the most complicated processes that occur during postnatal life. Humans and other large organisms heal by forming fibrotic scar tissue with diminished function, while smaller organisms respond with scarless tissue regeneration and functional restoration. Well-established scaling principles reveal that organism size exponentially correlates with peak tissue forces during movement, and evolutionary responses have compensated by strengthening organ-level mechanical properties. How these adaptations may affect tissue injury has not been previously examined in large animals and humans. Here, we show that blocking mechanotransduction signaling through the focal adhesion kinase pathway in large animals significantly accelerates wound healing and enhances regeneration of skin with secondary structures such as hair follicles. In human cells, we demonstrate that mechanical forces shift fibroblasts toward pro-fibrotic phenotypes driven by ERK-YAP activation, leading to myofibroblast differentiation and excessive collagen production. Disruption of mechanical signaling specifically abrogates these responses and instead promotes regenerative fibroblast clusters characterized by AKT-EGR1.
Humans and other large mammals heal wounds by forming fibrotic scar tissue with diminished function. Here, the authors show that disrupting mechanotransduction through the focal adhesion kinase pathway in large animals accelerates healing, prevents fibrosis, and enhances skin regeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Division of Plastic and Reconstructive Surgery, Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 Division of Plastic and Reconstructive Surgery, Stanford University School of Medicine, Department of Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); University Hospital Regensburg and Caritas Hospital St. Josef, University Center for Plastic, Reconstructive, Aesthetic and Hand Surgery, Regensburg, Germany (GRID:grid.411941.8) (ISNI:0000 0000 9194 7179)
3 Clinical Bioinformatics, Saarland University, Saarbruecken, Germany (GRID:grid.11749.3a) (ISNI:0000 0001 2167 7588)
4 Biomaterials and Advanced Drug Delivery Laboratory, Stanford University, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 Clinical Bioinformatics, Saarland University, Saarbruecken, Germany (GRID:grid.11749.3a) (ISNI:0000 0001 2167 7588); Stanford University, Department of Neurology & Neurological Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)